Matthäus Getlik

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

William Pao, Thomas Zander, Martin Peifer, 2009, Proceedings of the National Academy of Sciences.

Prevalent p53 mutants co-opt chromatin pathways to drive cancer growth

Cheryl H. Arrowsmith, Greg Donahue, Ali Shilatifard, 2015, Nature.

A new screening assay for allosteric inhibitors of cSrc.

Daniel Rauh, C. Grütter, D. Rauh, 2009, Nature chemical biology.

Proteus in the World of Proteins: Conformational Changes in Protein Kinases

Daniel Rauh, D. Rauh, Matthäus Getlik, 2010, Archiv der Pharmazie.

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.

Jochen Heil, Franziska Hoffgaard, Julian Engel, 2015, Journal of medicinal chemistry.

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.

Martin Peifer, Daniel Rauh, Lars Ruddigkeit, 2010, Cancer research.

Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.

Daniel Rauh, Jeffrey R. Simard, C. Grütter, 2009, Journal of the American Chemical Society.